Nemaura Medical touts precision data for non-invasive glucose monitor

Nemaura Medical (OTC:NMRD) touted precision data today from the on-going European clinical trial program of its non-invasive, needle-free glucose monitoring system, sugarBeat.

The study included 16 patients with Type I and Type II diabetes. The participants wore two sugarBeat skin-patches simultaneously over 3 days for up to 14 hours each day.

Get the full story at our sister site, Drug Delivery Business News.

 

The post Nemaura Medical touts precision data for non-invasive glucose monitor appeared first on MassDevice.

from MassDevice http://ift.tt/2kokYfM